Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04657094 · ClinicalTrials.gov registry record · Phase 2

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

A Phase 2 study of Chronic Lymphocytic Leukemia and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 2
Development phase
4
Enrollment target
1
Study location

NCT04657094 is a Phase 2 study of Chronic Lymphocytic Leukemia and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 4 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04657094, a Phase 2 study of Chronic Lymphocytic Leukemia and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the effect of acalabrutinib in treating autoimmune hemolytic anemia that has come back (relapsed) or has not responded to previous treatment (refractory) in patients with chronic lymphocytic leukemia. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Conditions Studied

Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Warm Antibody Autoimmune Hemolytic Anemia Autoimmune Hemolytic Anemia

Interventions

  • DRUG Acalabrutinib

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2021-03-16
Est. Completion 2026-02-27
Phase Phase 2

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04657094

The ClinicalTrials.gov registry entry for NCT04657094 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (98% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Acalabrutinib is the first listed.

NCT04657094 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04657094 about?

NCT04657094 is a clinical study titled "Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia". This phase II trial studies the effect of acalabrutinib in treating autoimmune hemolytic anemia that has come back (relapsed) or has not responded to previous treatment (refractory) in patients with chronic lymphocytic leukemia. Acalabrutinib may stop the growth of cancer cells by blocking some of t...

What is the current status of trial NCT04657094?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2021-03-16. Estimated completion is 2026-02-27.

What conditions does trial NCT04657094 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia.

What interventions are being tested in trial NCT04657094?

The interventions under investigation include: Acalabrutinib (DRUG).

Who is sponsoring clinical trial NCT04657094?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04657094 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.